Vitura Health Limited · ASX:VIT
Vitura Health — FY2026 Earnings Presentation
22 slides from Vitura Health's earnings presentation, Aug 26, 2026
Slide 1: Full-Year FY2026 Results Investor Webinar
For personal use only FULL-YEAR FY2026 RESULTS INVESTOR WEBINAR WEDNESDAY, 26 AUGUST 2026 10.00AM (AEST) Justin James – Chief Executive Officer Tom Howitt – Interim Chief Financial Officer COMMERCIAL IN CONFIDENCE 1
Slide 2: Introductions
Introductions For personal use only Justin James Tom Howitt CEO Interim CFO Vitura Health Limited Business Update and H1 FY2024 Results Investor Presentation 26 February 2024
Slide 3: Agenda
AGENDA For personal use only • Company Overview • FY2026 Highlights, Financials & Leadership Update • The Path Forward: Immediate Priorities • Conclusion / Questions Vitura Health Limited 3
Slide 4: Company Overview
For personal use only COMPANY OVERVIEW
Slide 5: Vision & Mission
Vision & Mission Vision // For personal use only To lead the future of healthcare access in specialty and emerging therapies. Mission // Build a connected ecosystem of patients, clinicians, pharmacies and suppliers through a seamless platform that delivers trusted access to specialty and emerging th
Slide 6: Vitura's unique digital health ecosystem
Vitura’s unique digital health ecosystem • Fully integrated end-to-end digital health platform. For personal use only • Distribution, logistics and route-to-market services for licensed wholesale supply of products including: - Medicinal Cannabis - Therapeutic Nicotine Vaping Products - MDMA and Psi
Slide 7: Vitura Overview – Operational Segmentation
Vitura Overview – Operational Segmentation General Practice Clinic Specialty Clinics Marketplace For personal use only Products Vitura Health Limited 7
Slide 8: FY2026 Highlights, Financials & Leadership Update
FY2026 Highlights, Financials & Leadership Update For personal use only
Slide 9: Full-Year FY2026 revenue
Full-Year FY2026 revenue For personal use only Sales and Distribution Revenue Total revenue for FY2026 of $131.2M - UP 5.7% YOY Medicinal Cannabis Products Nicotine Vaping Products • Sales and distribution: $100.4M – UP 4.2% YOY Clinics and Services Revenue • Clinics and services: $30.8M – UP 11.3%
Slide 10: Full-Year FY2026 Financial Results – Revenue Growth
Full-Year FY2026 Financial Results – Revenue Growth Key Points • Revenue growth continued For personal use only o Full-year FY2026 revenue of $131.2m - UP 5.7% vs PCP, driven from sales and distribution of medicinal cannabis and Nicotine Vaping Products (NVPs) and further growth in DoD revenue. o Bu
Slide 11: Full-Year FY2026 Financial Results - Revenue Growth
Full-Year FY2026 Financial Results - Revenue Growth Key Points • Doctors on Demand growth For personal use only o 13% growth in revenue compared to PCP. o Total consultation numbers up 11% YOY to 420,000+. • Candor adds to patient numbers / reduces waiting times o Added value by providing access to
Slide 12: Leadership Transition in FY26
Leadership Transition in FY26 Key Points For personal use only o Leadership transition occurred in January 2026, with the departure of previous CEO. o Chief Revenue Officer (Ryan Tattle) assumed responsibility for day-to-day management, supported by Non-Executive Director (Shane Tanner) to provide e
Slide 13: Full-Year FY2026 Financial Results – Overall Summary
Full-Year FY2026 Financial Results – Overall Summary A$M FY2026 FY2025 For personal use only Operating revenue 131.2 124.0 Normalised EBITDA note 3.0 8.9 Net Profit/(Loss) After Tax (NPAT) (4.4) 3.1 Normalised NPAT 0.1 3.9 Normalised Earnings Per Share (cents) 0.02 0.64 Note: Normalised for costs re
Slide 14: Full-Year FY2026 Financial Results – Overall Summary
Full-Year FY2026 Financial Results – Overall Summary Key Points For personal use only • Challenging FY26 environment in the marketplace and internally. • Revenue increase was offset by MC pricing compression and competition. • Overall consolidated loss – 4.4M. • Immediate action already taken to imp
Slide 15: The Path Forward and Immediate Priorities
THE PATH FORWARD AND IMMEDIATE PRIORITIES For personal use only
Slide 16: Accelerated Execution of Strategy and Focus
Accelerated Execution of Strategy and Focus For personal use only STRENGTHEN EXPAND STRENGTHEN TEAM AND CUSTOMER TECHNOLOGY FINANCIAL MARKET COMPANY AND MARKET ENHANCEMENT IMPROVEMENT POSITION CULTURE BASE Vitura Health Limited 16
Slide 17: Focus on Accelerated Execution and Improved Results
Focus on Accelerated Execution and Improved Results. Key Points For personal use only o Justin James started as Vitura CEO on 1 June 2026. o New streamlined leadership team, structural savings, focus and energy. - New CFO, James Frayne – starting 1 October 2026; - New EGM Strategy, Technology & Risk
Slide 18: Emerging Opportunities & The Path Forward
Emerging Opportunities & The Path Forward For personal use only • Leaner leadership structure and Q4 efficiencies already delivered circa $1M annually in savings. • Future overall cost base to be better aligned with Vitura’s operations. • Comprehensive strategic business review also underway. • Clea
Slide 19: Emerging Opportunities and The Path Forward
Emerging Opportunities and The Path Forward For personal use only • Improve the balance between volume and profitability on medicinal cannabis sales by driving more value over volume. • Deepen industry partnerships to continue growth in medicinal NVPs for smoking cessation. • Grow supply of MDMA-ass
Slide 20: Conclusion
Conclusion For personal use only • Create positive patient experiences and receive a fairer value exchange for the products and services we offer. • Emphasis on returning to sustainable profitability from FY2027 onwards. • Demonstrated cost control to continue. • New leaner leadership team with clea
Slide 21: Disclaimer applying to this Presentation
Disclaimer applying to this Presentation The following disclaimer applies to this presentation (Presentation) You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation h
Slide 22: Q&A
Q&A For personal use only vitura.com.au VITURA HEALTH LIMITED ASX : VIT info@vitura.com.au 1300 799 491